Pacer Advisors Inc. Has $104.87 Million Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Key Points

• Pacer Advisors Inc. reduced its stake in Jazz Pharmaceuticals PLC by 61.9%, selling 1,369,775 shares and now holds 844,705 shares valued at approximately $104.87 million.
• In its most recent earnings report, Jazz Pharmaceuticals missed EPS estimates, reporting $1.68 compared to the anticipated $4.65, with revenue also falling short of expectations at $897.84 million.
• Institutional investors currently hold 89.14% of Jazz Pharmaceuticals' stock, highlighting significant interest from major investment firms in the specialty pharmaceutical company.

Pacer Advisors Inc. decreased its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 61.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 844,705 shares of the specialty pharmaceutical company's stock after selling 1,369,775 shares during the period. Pacer Advisors Inc. owned 1.37% of Jazz Pharmaceuticals worth $104,870,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in JAZZ. Quadrant Capital Group LLC raised its stake in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after acquiring an additional 101 shares in the last quarter. Elequin Capital LP raised its stake in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after acquiring an additional 183 shares in the last quarter. CoreFirst Bank & Trust bought a new stake in Jazz Pharmaceuticals during the 4th quarter valued at $28,000. Allianz SE bought a new stake in Jazz Pharmaceuticals during the 4th quarter valued at $29,000. Finally, Parallel Advisors LLC raised its stake in Jazz Pharmaceuticals by 85.6% during the 1st quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after acquiring an additional 119 shares in the last quarter. Institutional investors own 89.14% of the company's stock.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $116.35, for a total value of $116,350.00. Following the transaction, the chief executive officer owned 439,307 shares in the company, valued at $51,113,369.45. The trade was a 0.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Seamus Mulligan bought 100,000 shares of the stock in a transaction on Friday, May 9th. The stock was purchased at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the purchase, the director directly owned 100,000 shares of the company's stock, valued at approximately $9,826,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 2,500 shares of company stock worth $277,930 in the last 90 days. Corporate insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on JAZZ. Piper Sandler reissued an "overweight" rating and issued a $147.00 price objective (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Wall Street Zen downgraded Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Needham & Company LLC reissued a "buy" rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 11th. Royal Bank Of Canada decreased their target price on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Finally, Morgan Stanley decreased their target price on Jazz Pharmaceuticals from $166.00 to $165.00 and set an "overweight" rating on the stock in a report on Tuesday, July 22nd. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $181.64.

Jazz Pharmaceuticals Stock Down 1.7%

Shares of JAZZ stock traded down $1.95 on Tuesday, reaching $115.43. 144,936 shares of the company's stock traded hands, compared to its average volume of 963,712. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.97 and a current ratio of 3.38. The company has a market capitalization of $6.98 billion, a P/E ratio of 15.40, a price-to-earnings-growth ratio of 5.69 and a beta of 0.32. The business's 50 day moving average price is $110.37 and its two-hundred day moving average price is $118.02.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The firm had revenue of $897.84 million during the quarter, compared to analysts' expectations of $984.16 million. During the same quarter last year, the firm earned $2.68 EPS. The business's revenue for the quarter was down .5% compared to the same quarter last year. On average, equities analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.